Category News

GigaGen Secures U.S. BARDA Contract to Develop Antibody Therapies for Botulinum Neurotoxins and Biothreats

GigaGen Inc., a biotechnology firm specializing in innovative antibody treatments for immunodeficiencies, infectious diseases, and cancers resistant to checkpoint inhibitors, has announced a new contract awarded by the Biomedical Advanced Research and Development Authority (BARDA). BARDA, part of the U.S.…

Read MoreGigaGen Secures U.S. BARDA Contract to Develop Antibody Therapies for Botulinum Neurotoxins and Biothreats

Enhertu Receives Priority Review in the US for HER2-Low/Ultralow Metastatic Breast Cancer Post-Endocrine Therapy

AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to their supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan). This review is for the treatment of adult patients…

Read MoreEnhertu Receives Priority Review in the US for HER2-Low/Ultralow Metastatic Breast Cancer Post-Endocrine Therapy

Calquence Receives Priority Review in the U.S. for Newly Diagnosed Mantle Cell Lymphoma Patients

AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). This designation is granted…

Read MoreCalquence Receives Priority Review in the U.S. for Newly Diagnosed Mantle Cell Lymphoma Patients

AIVITA Biomedical Partners with LevEllis to License Innovative Skincare Formulations

AIVITA Biomedical, Inc., a biotech firm focused on pioneering stem cell applications, has announced a licensing agreement with LevEllis, a global skincare retailer. This partnership grants LevEllis the exclusive worldwide marketing and distribution rights to AIVITA’s proprietary skincare formulations, previously…

Read MoreAIVITA Biomedical Partners with LevEllis to License Innovative Skincare Formulations

ImmunoPrecise Subsidiary Enters Material Transfer Agreement with Biotheus

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an AI-driven biotherapeutics and technology company, and Biotheus Inc., a clinical-stage biotech specializing in biologics for oncology and inflammatory diseases, have announced the signing of a Material Transfer and Evaluation Agreement (MTEA). This agreement…

Read MoreImmunoPrecise Subsidiary Enters Material Transfer Agreement with Biotheus

Arcus Biosciences to Trial Casdatifan and Volrustomig Combo in Renal Cancer

Arcus Biosciences, Inc. (NYSE: RCUS), a global biopharmaceutical company in the clinical stage, focused on developing innovative molecules and combination therapies for cancer patients, has announced a new collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN). The partnership aims to evaluate the combination…

Read MoreArcus Biosciences to Trial Casdatifan and Volrustomig Combo in Renal Cancer

Repare Therapeutics Presents Phase 1 Data on Camonsertib with Radiotherapy at ASTRO

Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, recently announced promising data from a study evaluating camonsertib, an oral small molecule ATR inhibitor, in combination with palliative radiation for treating metastatic tumors with an ataxia-telangiectasia-mutated (ATM) mutation. The…

Read MoreRepare Therapeutics Presents Phase 1 Data on Camonsertib with Radiotherapy at ASTRO